Regulation of Aryl Hydrocarbon Receptor Interacting Protein (AIP) Protein Expression by MiR-34a in Sporadic Somatotropinomas

Familial Isolated Pituitary Adenomas (FIPA) and the Pituitary Adenoma Predisposition due to Mutations in the Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene

(2013) Albert Beckers et al.   ENDOCRINE REVIEWS

Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern

(2013) Leandro Kasuki et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

MicroRNA miR-107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor-interacting protein in vitro

(2012) Giampaolo Trivellin et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression

(2012) Leandro Kasuki et al.   ENDOCRINE-RELATED CANCER

Altered MicroRNA Expression Profile in Human Pituitary GH Adenomas: Down-Regulation of miRNA Targeting HMGA1, HMGA2, and E2F1

(2012) Daniela D'Angelo et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Somatostatin Analogs Modulate AIP in Somatotroph Adenomas: The Role of the ZAC1 Pathway

(2012) Harvinder S. Chahal et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Functional screen analysis reveals miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation of the PTEN–AKT pathway

(2012) T Palumbo et al.   ONCOGENE

Should aip gene screening be recommended in family members of FIPA patients with R16H variant?

(2012) Maria Chiara Zatelli et al.   Pituitary

MicroRNA-34a Inhibits the Proliferation and Metastasis of Osteosarcoma Cells Both In Vitro and In Vivo

(2012) Kang Yan et al.   PLoS One

Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function

(2012) B. C. Bernardo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Novel pathway for somatostatin analogs in patients with acromegaly

(2012) Mônica R. Gadelha et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Recomendações do Departamento de Neuroendocrinologia da Sociedade Brasileira de Endocrinologia e Metabologia para o diagnóstico e tratamento da acromegalia no Brasil

(2011) Leonardo Vieira Neto et al.   Arquivos Brasileiros de Endocrinologia e Metabologia

miRNA-34a is associated with docetaxel resistance in human breast cancer cells

(2011) L. Kastl et al.   BREAST CANCER RESEARCH AND TREATMENT

Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly

(2011) Stine Lyngvi Fougner et al.   CLINICAL ENDOCRINOLOGY

Myc overexpression brings out unexpected antiapoptotic effects of miR-34a

(2011) E Sotillo et al.   ONCOGENE

Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas

(2011) Markus Vogt et al.   VIRCHOWS ARCHIV

Regulation of mRNA Translation and Stability by microRNAs

(2010) Marc Robert Fabian et al.   Annual Review of Biochemistry

Differential expression of microRNAs in GH-secreting pituitary adenomas

(2010) Zhi-Gang Mao et al.   Diagnostic Pathology

Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families

(2010) Susana Igreja et al.   HUMAN MUTATION

Clinical Characteristics and Therapeutic Responses in Patients with Germ-LineAIPMutations and Pituitary Adenomas: An International Collaborative Study

(2010) Adrian F. Daly et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A Consensus on Criteria for Cure of Acromegaly

(2010) A. Giustina et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

miRNAs in human cancer

(2010) Thalia A Farazi et al.   JOURNAL OF PATHOLOGY

MicroRNA-132–mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis

(2010) Sudarshan Anand et al.   NATURE MEDICINE

Low Aryl Hydrocarbon Receptor-Interacting Protein Expression Is a Better Marker of Invasiveness in Somatotropinomas than Ki-67 and p53

(2010) Leandro Kasuki Jomori de Pinho et al.   NEUROENDOCRINOLOGY

QPCR: Application for real-time PCR data management and analysis

(2009) Stephan Pabinger et al.   BMC BIOINFORMATICS

Origins and Mechanisms of miRNAs and siRNAs

(2009) Richard W. Carthew et al.   CELL

The miR-34 family in cancer and apoptosis

(2009) H Hermeking   CELL DEATH AND DIFFERENTIATION

Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications

(2009) Marie-Lise Jaffrain-Rea et al.   ENDOCRINE-RELATED CANCER

Clinicopathological Features of Growth Hormone-producing Pituitary Adenomas: Difference among Various Types Defined by Cytokeratin Distribution Pattern Including a Transitional Form

(2008) Abdulkader Obari et al.   ENDOCRINE PATHOLOGY

The Role of the Aryl Hydrocarbon Receptor-Interacting Protein Gene in Familial and Sporadic Pituitary Adenomas

(2008) Chrysanthia A. Leontiou et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM